Drugs for Gastrointestinal Diseases — MCQs

Drugs for Gastrointestinal Diseases Indian Medical PG Practice Questions and MCQs

Question 261: Which newer aminosalicylate is known to cause watery diarrhea due to increased secretion of fluid in the small bowel?

A. Olsalazine (Correct Answer)
B. 5-ASA
C. Mesalamine
D. Balsalazide

Explanation: ### Explanation **Correct Answer: A. Olsalazine** **Mechanism and Rationale:** Olsalazine is a prodrug consisting of two molecules of **5-ASA (Mesalamine)** linked by an azo bond. This bond is cleaved by colonic bacteria to release the active drug in the colon. However, olsalazine has a unique side effect: it stimulates **secretory diarrhea** in approximately 10–15% of patients. This occurs because the unabsorbed olsalazine molecule promotes the secretion of chloride and water in the small bowel (via a cyclic AMP-mediated mechanism) before it reaches the colon for cleavage. This "watery diarrhea" is a classic, high-yield side effect that often limits its clinical use compared to other aminosalicylates. **Analysis of Incorrect Options:** * **B. 5-ASA & C. Mesalamine:** These are the same compound. Mesalamine is the active moiety used in Ulcerative Colitis. While it can cause GI upset or headache, it is not specifically associated with the paradoxical induction of secretory diarrhea; in fact, it is used to *treat* the inflammation that causes diarrhea. * **D. Balsalazide:** This is another prodrug where 5-ASA is linked to an inert carrier (4-aminobenzoyl-β-alanine). Like olsalazine, it is activated in the colon, but it does not possess the same secretagogue effect on the small intestinal mucosa and is generally better tolerated. **NEET-PG High-Yield Pearls:** * **Sulfasalazine** (5-ASA + Sulfapyridine) is the older prototype. Its side effects (malaise, hemolysis, sperm count reduction) are mostly due to the **Sulfapyridine** moiety. * **Olsalazine and Balsalazide** were developed to deliver 5-ASA to the colon while avoiding the toxicity of sulfapyridine. * **Key Distinction:** If a question mentions "diarrhea as a side effect" in a patient being treated for "bloody diarrhea (UC)," think **Olsalazine**.

Question 262: Ondansetron acts by:

A. Action on CTZ (Correct Answer)
B. 5-HT3 antagonism
C. D1 and D2 receptor antagonism
D. Increasing GIT motility

Explanation: **Explanation:** **Ondansetron** is a potent antiemetic primarily used to control chemotherapy-induced nausea and vomiting (CINV). **Why Option A is correct:** The primary site of action for Ondansetron is the **Chemoreceptor Trigger Zone (CTZ)** located in the *Area Postrema* of the medulla. The CTZ is rich in 5-HT3 receptors. By blocking these receptors, Ondansetron prevents the activation of the vomiting center. While it also works on peripheral vagal nerve terminals in the gastrointestinal tract, its central action on the CTZ is the definitive mechanism for its potent antiemetic effect. **Why other options are incorrect:** * **Option B:** While Ondansetron is indeed a **5-HT3 antagonist**, in the context of this specific question format (often seen in older NEET-PG/AIIMS patterns), the "Action on CTZ" is considered the anatomical site of action, whereas 5-HT3 antagonism is the molecular mechanism. If both are present, the site (CTZ) is often prioritized as the primary answer. * **Option C:** D1 and D2 receptor antagonism is the mechanism of drugs like **Metoclopramide** and **Domperidone**, not Ondansetron. * **Option D:** Increasing GIT motility (Prokinetic action) is characteristic of drugs like Metoclopramide and Cisapride. Ondansetron actually tends to **decrease** colonic motility, often leading to constipation. **High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice:** For CINV and post-operative nausea and vomiting (PONV). * **Side Effects:** The most common side effect is **headache**. It is also notorious for causing **QT interval prolongation** and **constipation**. * **Metabolism:** It is metabolized by the liver; dose adjustment is required in severe hepatic impairment. * **Note:** It is *not* effective in motion sickness (where H1 and M1 blockers are used).

Question 263: All of the following drugs are used for eradication of Helicobacter pylori except?

A. Bismuth subcitrate
B. Sucralfate (Correct Answer)
C. Metronidazole
D. Moxifloxacin

Explanation: **Explanation:** The goal of *Helicobacter pylori* eradication is to eliminate the bacteria using a combination of acid suppressants (PPIs) and antimicrobial agents. **Why Sucralfate is the correct answer:** **Sucralfate** is a complex of sulfated sucrose and aluminum hydroxide. It acts as a **physical mucosal protective agent** by polymerizing in an acidic environment (pH < 4) to form a sticky paste that adheres to the ulcer base. While it promotes healing and provides a barrier against acid and pepsin, it possesses **no intrinsic antibacterial activity** against *H. pylori*. Therefore, it is not included in standard eradication regimens (Triple or Quadruple therapy). **Analysis of incorrect options:** * **Bismuth subcitrate (Option A):** This is a key component of **Bismuth-based Quadruple Therapy**. It has direct toxic effects on *H. pylori*, inhibits its enzymes (urease, catalase), and prevents bacterial adhesion to the gastric epithelium. * **Metronidazole (Option C):** An imidazole antibiotic frequently used in both Triple and Quadruple therapies, especially in patients allergic to penicillin or in areas with low nitroimidazole resistance. * **Moxifloxacin (Option D):** A second-line fluoroquinolone used in **"Rescue Therapy"** for patients who have failed initial standard treatments. **NEET-PG High-Yield Pearls:** 1. **Standard Triple Therapy (7-14 days):** PPI + Amoxicillin + Clarithromycin (Mnemonic: **PAC**). 2. **Bismuth Quadruple Therapy:** PPI + Bismuth + Metronidazole + Tetracycline (Mnemonic: **PBM-T**). This is now preferred in areas with high clarithromycin resistance. 3. **Sequential Therapy:** 5 days of PPI + Amoxicillin, followed by 5 days of PPI + Clarithromycin + Tinidazole. 4. **Sucralfate Note:** It requires an acidic medium to work; therefore, it should **not** be administered simultaneously with antacids or PPIs (give it 1 hour before meals).

Question 264: What is the drug of choice for Zollinger-Ellison syndrome?

A. Antihistamines
B. Proton pump inhibitors (Correct Answer)
C. Dopamine agonists
D. Antacids

Explanation: ### Explanation **Correct Answer: B. Proton pump inhibitors (PPIs)** **Mechanism and Rationale:** Zollinger-Ellison Syndrome (ZES) is caused by a gastrin-secreting tumor (gastrinoma), typically located in the pancreas or duodenum. This leads to extreme hypergastrinemia, which overstimulates the parietal cells to secrete massive amounts of gastric acid. **Proton Pump Inhibitors (PPIs)** like Omeprazole or Pantoprazole are the drugs of choice because they inhibit the **H+/K+ ATPase pump**, which is the "final common pathway" for acid secretion [1]. Unlike other drugs, PPIs can achieve near-complete suppression of acid regardless of whether the stimulus is gastrin, histamine, or acetylcholine. In ZES, PPIs are often administered at much higher doses than those used for standard peptic ulcer disease [1]. **Why Other Options are Incorrect:** * **A. Antihistamines (H2 Blockers):** While H2 blockers (e.g., Ranitidine) reduce acid, they only block one pathway. In ZES, the massive gastrin levels easily overcome H2 blockade, making them significantly less effective than PPIs. * **C. Dopamine agonists:** These have no role in suppressing gastric acid. Dopamine *antagonists* (like Metoclopramide) are used as prokinetics, but not for acid-peptic disorders. * **D. Antacids:** These only neutralize existing acid and have a very short duration of action. They cannot counteract the continuous, massive acid production seen in ZES. **High-Yield Clinical Pearls for NEET-PG:** * **Diagnosis:** ZES is suspected when a patient has multiple, refractory, or distal duodenal ulcers. The screening test is **fasting serum gastrin levels** (>1000 pg/mL is diagnostic). * **Localization:** The **Somatostatin Receptor Scintigraphy (SRS)** is the most sensitive imaging modality for locating the gastrinoma. * **Association:** Approximately 25% of ZES cases are associated with **Multiple Endocrine Neoplasia Type 1 (MEN1)**. * **Definitive Treatment:** Surgical resection of the tumor is the only curative treatment; PPIs provide symptomatic and medical management [1].

Question 265: Which of the following statements about Racecadotril is false?

A. It is a peripheral acting enkephalinase inhibitor.
B. It is a drug used in constipation. (Correct Answer)
C. It is metabolized by the liver.
D. It has antisecretory action on the GIT.

Explanation: **Explanation:** **Racecadotril** is an **antidiarrheal** agent, specifically an **enkephalinase inhibitor**. Its primary mechanism involves preventing the breakdown of endogenous enkephalins (opioid peptides) in the gastrointestinal tract. 1. **Why Option B is the correct (False) statement:** Racecadotril is used to treat **acute secretory diarrhea**, not constipation. By protecting enkephalins, it activates delta-opioid receptors, which decreases the levels of cAMP in the intestinal mucosa. This leads to a potent **antisecretory effect**, reducing the hypersecretion of water and electrolytes into the gut lumen. 2. **Analysis of other options:** * **Option A (True):** It acts peripherally on the enkephalinase enzyme located in the intestinal epithelium. It does not cross the blood-brain barrier, thus avoiding central opioid side effects. * **Option C (True):** Racecadotril is a prodrug. After oral administration, it is rapidly absorbed and **metabolized by the liver** into its active metabolite, thiorphan. * **Option D (True):** Its hallmark is its **antisecretory action**. Unlike loperamide, it does not significantly affect intestinal motility (transit time), which reduces the risk of secondary constipation or abdominal bloating. **High-Yield NEET-PG Pearls:** * **Indication:** Preferred in pediatric diarrhea because it does not cause respiratory depression or paralytic ileus (unlike loperamide). * **Mechanism:** Increases endogenous enkephalins $\rightarrow$ $\downarrow$ cAMP $\rightarrow$ $\downarrow$ water/electrolyte secretion. * **Key Advantage:** It treats diarrhea without causing "rebound constipation." * **Contraindication:** Avoid in diarrhea with blood or pus (dysentery) where antibiotics are primarily required.

Question 266: All of the following are bulk-forming laxatives except?

A. Polycarbophil
B. Psyllium
C. Methylcellulose
D. Glycerin (Correct Answer)

Explanation: **Explanation:** The correct answer is **D. Glycerin**. **Mechanism of Action:** Bulk-forming laxatives are indigestible hydrophilic colloids that absorb water, forming a bulky, soft gel that distends the colon and promotes peristalsis. **Glycerin**, however, is an **osmotic/stimulant laxative** (specifically a lubricant/irritant when used as a suppository). It works by drawing water into the stool through osmosis and locally irritating the rectal mucosa to induce a bowel movement, typically within 15–30 minutes. **Analysis of Options:** * **A. Polycarbophil:** A synthetic hydrophilic resin that acts as a bulk-forming agent. It is often preferred because it produces less intestinal gas than natural fibers. * **B. Psyllium (Ispaghula):** A natural vegetable mucilloid derived from plant seeds. It is the most commonly used bulk-forming laxative. * **C. Methylcellulose:** A semi-synthetic cellulose derivative that dissolves in water to form a colloidal solution, acting as a classic bulk-forming agent. **NEET-PG High-Yield Pearls:** * **First-line therapy:** Bulk-forming laxatives are the safest and preferred first-line treatment for chronic constipation. * **Hydration:** Patients must be advised to take these with **plenty of water**; otherwise, they can cause intestinal obstruction or fecal impaction. * **Contraindication:** Avoid bulk-forming agents in patients with megacolon or intestinal strictures. * **Glycerin usage:** Primarily used in pediatric populations or for acute evacuation of the lower bowel via the rectal route.

Question 267: What is the drug of choice for NSAID-induced peptic ulcer disease?

A. Pirenzapine
B. Omeprazole (Correct Answer)
C. Cimetidine
D. Misoprostol

Explanation: **Explanation:** The correct answer is **Omeprazole (Option B)**. **1. Why Omeprazole is the Drug of Choice:** Proton Pump Inhibitors (PPIs) like Omeprazole are the **drugs of choice (DOC)** for both the treatment and prevention of NSAID-induced peptic ulcers. NSAIDs inhibit COX-1, leading to decreased prostaglandin synthesis, which reduces gastric mucosal protection. PPIs are superior because they provide profound acid suppression, allowing the ulcer to heal even if the patient continues NSAID therapy. They are more effective and better tolerated than H2 blockers or Misoprostol. **2. Analysis of Incorrect Options:** * **Pirenzapine (A):** An M1-selective anticholinergic. It reduces acid secretion but is significantly less effective than PPIs and is rarely used clinically due to side effects. * **Cimetidine (C):** An H2-receptor antagonist. While it can heal NSAID-induced ulcers, it is less effective than PPIs, especially for gastric ulcers, and has a shorter duration of action and more drug interactions. * **Misoprostol (D):** A PGE1 analogue. While Misoprostol is specifically designed to replace the prostaglandins lost due to NSAID use, it is **not** the DOC because of its frequent side effects (diarrhea, abdominal cramps) and the need for multiple daily dosing. **3. NEET-PG High-Yield Pearls:** * **Prophylaxis:** PPIs are also the DOC for the prevention of ulcers in patients requiring long-term NSAID therapy. * **Misoprostol:** Specifically indicated for preventing NSAID-induced ulcers in high-risk patients, but limited by GI toxicity. It is **contraindicated in pregnancy** (abortifacient). * **Zollinger-Ellison Syndrome:** PPIs are the DOC here as well. * **H. pylori:** PPIs are a mandatory component of the Triple/Quadruple eradication regimens.

Question 268: Which of the following drugs does NOT decrease gastric acid secretion?

A. Ranitidine
B. Omeprazole
C. Sucralfate (Correct Answer)
D. Pirenzepine

Explanation: **Explanation:** The correct answer is **Sucralfate** because it is a **cytoprotective agent**, not an antisecretory drug. It does not alter the pH of the gastric juice or inhibit the production of acid. **Why Sucralfate is correct:** Sucralfate is an aluminum salt of sulfated sucrose. In an acidic environment (pH < 4), it undergoes polymerization to form a sticky, viscous gel. This paste binds selectively to the exposed proteins (albumin, fibrinogen) in the ulcer base, creating a physical barrier against acid, pepsin, and bile. It "coats" the ulcer rather than stopping acid production. **Why the other options are incorrect:** * **Ranitidine:** Is an **$H_2$ receptor antagonist**. It competitively inhibits histamine at the $H_2$ receptors on gastric parietal cells, significantly decreasing basal and stimulated acid secretion. * **Omeprazole:** Is a **Proton Pump Inhibitor (PPI)**. It irreversibly inhibits the $H^+/K^+$-ATPase pump in the parietal cells, which is the final common pathway for acid secretion. It is the most potent acid suppressant. * **Pirenzepine:** Is a selective **$M_1$ anticholinergic** drug. It reduces gastric acid secretion by blocking $M_1$ receptors on paracrine cells, thereby reducing histamine release. **NEET-PG High-Yield Pearls:** * **Administration:** Sucralfate requires an acidic medium for activation; therefore, it should **not** be given simultaneously with antacids, $H_2$ blockers, or PPIs (take it 1 hour before meals). * **Side Effects:** The most common side effect of Sucralfate is **constipation** (due to the aluminum content). * **Drug Interactions:** It can adsorb other drugs (e.g., Tetracycline, Digoxin, Phenytoin), reducing their absorption. * **Pirenzepine** is rarely used clinically now due to the superior efficacy of PPIs but remains a classic pharmacological example of an $M_1$ blocker.

Question 269: Which of the following drugs used in the management of peptic ulcers can cause gynecomastia?

A. Sucralfate
B. Cimetidine (Correct Answer)
C. Pirenzepine
D. Rabeprazole

Explanation: **Explanation:** **Cimetidine** is a first-generation H2-receptor antagonist. It is the only drug in its class notorious for causing **gynecomastia** and erectile dysfunction. This occurs through two primary mechanisms: 1. **Anti-androgenic effect:** It binds to androgen receptors and inhibits the action of dihydrotestosterone (DHT). 2. **Hyperprolactinemia:** It inhibits the metabolism of estradiol and increases serum prolactin levels by inhibiting the breakdown of estrogen in the liver. **Analysis of Incorrect Options:** * **Sucralfate (A):** A physical mucosal protectant that forms a "sticky" polymer over the ulcer base. It is not absorbed systemically and has no hormonal side effects. * **Pirenzepine (C):** A selective M1-anticholinergic drug that reduces gastric acid secretion. Its side effects are typically atropine-like (dry mouth, blurred vision) rather than hormonal. * **Rabeprazole (D):** A Proton Pump Inhibitor (PPI). While PPIs are more potent than H2 blockers, they do not possess anti-androgenic properties. **High-Yield Clinical Pearls for NEET-PG:** * **Enzyme Inhibition:** Cimetidine is a potent **Cytochrome P450 inhibitor**, leading to significant drug interactions (e.g., increasing levels of Warfarin, Phenytoin, and Theophylline). * **Newer H2 Blockers:** Ranitidine, Famotidine, and Roxatidine are more potent than Cimetidine and **do not** cause gynecomastia or significant P450 inhibition. * **Other Drugs causing Gynecomastia (Mnemonic: DISCO):** **D**igoxin, **I**soniazid, **S**pironolactone, **C**imetidine, **O**estrogens/Ketoconazole.

Question 270: All of the following are H2 blockers except?

A. Cimetidine
B. Ranitidine
C. Famotidine
D. Omeprazole (Correct Answer)

Explanation: **Explanation:** The correct answer is **D. Omeprazole**. This question tests the ability to differentiate between two major classes of acid-suppressing agents: H2 Receptor Antagonists (H2RAs) and Proton Pump Inhibitors (PPIs). **1. Why Omeprazole is the correct answer:** Omeprazole belongs to the **Proton Pump Inhibitor (PPI)** class. Unlike H2 blockers, which act on histamine receptors, PPIs irreversibly inhibit the **H+/K+ ATPase enzyme** (the "proton pump") located on the apical membrane of gastric parietal cells. This is the final common pathway of acid secretion, making PPIs more potent than H2 blockers. **2. Why the other options are incorrect:** * **A, B, and C (Cimetidine, Ranitidine, Famotidine):** These are all competitive **H2 Receptor Antagonists**. They work by blocking the H2 receptors on parietal cells, preventing histamine from stimulating acid production. They typically end in the suffix **"-tidine."** **Clinical Pearls for NEET-PG:** * **Cimetidine:** It is the "prototype" H2 blocker but is now less used due to its side effect profile. It is a potent **P450 enzyme inhibitor** (causing drug interactions with warfarin, phenytoin) and has **anti-androgenic effects** (causing gynecomastia and galactorrhea). * **Potency:** Among H2 blockers, **Famotidine** is the most potent, while Cimetidine is the least. * **Drug of Choice:** PPIs (like Omeprazole) are the drug of choice for GERD, Peptic Ulcer Disease, and Zollinger-Ellison Syndrome. * **Administration:** PPIs are prodrugs and should be taken 30 minutes **before meals** for maximum efficacy, as they require an acidic environment to be activated.

Practice by Chapter

Acid-Peptic Disease Therapeutics

Practice Questions

Proton Pump Inhibitors

Practice Questions

H2 Receptor Antagonists

Practice Questions

Antacids and Mucosal Protectants

Practice Questions

Antiemetics

Practice Questions

Prokinetic Agents

Practice Questions

Laxatives and Purging Agents

Practice Questions

Antidiarrheal Drugs

Practice Questions

Drugs for Inflammatory Bowel Disease

Practice Questions

Pancreatic Enzyme Supplements

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free